🏢 官网IRIDYAQwen · 实盘不做把握 2/10不做原因:不是事件
北京时间·🕒 发布 09-01 18:00:00·⟳ 抓取 09-01 18:08:56·⚡ 决策 09-02 01:14:57 +7h06m·55.8 天前
IDEAYA Biosciences 宣布11月伦敦投资者研发日及参加9月多场投资者会议
这是标准的投资者关系日程公告：参加4场卖方会议和宣布2.5个月后的R&D Day。不含任何新临床数据、财务指引、合作协议或监管进展。R&D Day 提及的'新临床前数据'要到11月16日才发布，今日无任何增量事实可供交易。
📄 原文IDYA↗ 原文
SOUTH SAN FRANCISCO, Calif. , Sept. 1, 2026 / PRNewswire / -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medi…
不做 IDEAYA Biosciences（IDYA.US）
纯日程性IR公告（会议参加+未来R&D Day预告），不含任何新临床数据、财务更新或业务实质信息，无可交易催化。R&D Day的新数据要到11月16日才发布，届时再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
IDEAYA 于2026年9月1日发布纯日程性IR公告，宣布参加9月多场投资者会议及11月伦敦R&D Day。公告不含新数据、财务更新、业务合作或监管进展。R&D Day 提及的'新临床前数据'为未来事件（11月16日），今日无任何可交易的增量信息。此类会议参加公告对股价无历史影响，属于典型非事件。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无
方向:不适用——纯日程公告无先例可比
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 257 ms
{"result": "search_processed_events:agent query=`ideaya biosciences investor r&d day london | ideaya mtap cdkn2a kras pancreatic cancer | idya conference participation september 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 67.7/72 小时、2987 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常
原文全文
展开原文 · 4,415 字
SOUTH SAN FRANCISCO, Calif.
,
Sept. 1, 2026
/
PRNewswire
/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT
IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
Advance registration is required for both in-person and virtual attendance. To register, please visit
https://lifescievents.com/event/izl51pw/
Wells Fargo 21
st
Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi
's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24
th
Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at
https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
,
Sept. 1, 2026
/
PRNewswire
/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT
IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
Advance registration is required for both in-person and virtual attendance. To register, please visit
https://lifescievents.com/event/izl51pw/
Wells Fargo 21
st
Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi
's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24
th
Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York
Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at
https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。